SMIP34

News alerts, weekly reports and conference planners

Company:

Evestra, UT Health Science Center

Drug class:

PELP1 inhibitor

‹

›

over1year

PELP1 is a novel therapeutic target in hepatocellular carcinoma. (PubMed, Cancer Res Commun)

Importantly, SMIP34, a first-in-class small molecule inhibitor targeting PELP1, effectively decreased the cell viability, clonogenic survival and invasiveness of HCC cells...Further, the knockdown or pharmacological inhibition of PELP1 significantly decelerated the HCC tumor growth in xenograft models. In summary, our study findings indicate that PELP1 could serve as a promising target for therapeutic intervention in HCC.

over 1 year ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PELP1 (Proline, Glutamate And Leucine Rich Protein 1)

SMIP34

over2years

PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. (PubMed, Mol Oncol)

Importantly, SMIP34 treatment resulted in a significant reduction of the growth of ECa xenografts. Collectively, these findings underscore the potential of SMIP34 in treating ECa.

over 2 years ago

Journal

PELP1 (Proline, Glutamate And Leucine Rich Protein 1)

sirolimus • SMIP34

over2years

Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34. (PubMed, Breast Cancer Res Treat)

Together, these findings from in vitro, ex vivo, and in vivo models show that SMIP34 may be a useful therapeutic agent for inhibiting PELP1 signaling in TNBC.

over 2 years ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • PELP1 (Proline, Glutamate And Leucine Rich Protein 1)

SMIP34